|Healthcare Review: Alnylam Pharmaceuticals, Dendreon Corporation, Hansen Medical, Gentium, Luminex Corporation|
|By Staff and Wire Reports|
|Wednesday, 16 January 2013 14:36|
A slow economic recovery in developed nations is holding back the global economy, the World Bank said on Tuesday, as it sharply scaled back its forecast for world growth in 2013 to 2.4 percent from an earlier forecast of 3.0 percent.
Following are the notable movers at mid day on Wednesday:
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares gained 6.61% to $21.46 in the morning hour after the company announced the pricing of an underwritten registered public offering of 8,000,000 shares of its common stock at a public offering price of $20.13 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 22, 2013, subject to the satisfaction of customary closing conditions.
Dendreon Corporation (NASDAQ:DNDN) shares increased 3.40% to $6.69 after the company, prior last week, announced preliminary revenues for the fourth quarter ended December 31, 2012. Net product revenue for the quarter is expected to be approximately $85.5 million, which includes an approximate $3.8 million favorable adjustment to the Company’s chargebacks reserve due to a change in estimate. On a pro-forma basis, excluding this adjustment, revenue for the quarter is expected to be approximately $81.6 million, up 5% on a sequential basis.
Hansen Medical, Inc. (NASDAQ:HNSN) stock jumped 3.17% to $2.27. The company, on Jan. 15, announced it will exhibit its Magellan Robotic System at the 25th Annual International Symposium on Endovascular Therapy (ISET), from January 19-23 at the Fontainebleau Miami Beach Hotel in Miami, FL. The Company will be exhibiting the Magellan Robotic System at Booth 509.
Gentium S.p.A. (ADR) (NASDAQ:GENT) stock gained 0.30% to $11.55. The company, on Dec. 18, announced that it has submitted responses to the second List of Outstanding Issues ("LoOIs") to the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") in connection with the Company's Marketing Authorization Application ("MAA") for Defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing haematopoietic stem cell transplantation therapy.
Luminex Corporation (NASDAQ:LMNX) shares gained 4.66% to $18.64 after the company announced yesterday that it has received FDA clearance for its xTAG Gastrointestinal Pathogen Panel (GPP), the first comprehensive molecular diagnostic assay that tests for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single assay. The xTAG GPP assay can be an important clinical tool in the management of gastrointestinal infections, and is now available in the United States.